Anti-inflammatory effects of neurotrophic therapy (a pilot study)

Abstract

The high clinical effect of neurotrophic therapy with cerebrolysin in MCI shows its anti-inflammatory and immunotropic action that suggests the impact of cerebrolysin on the pathogenesis of MCI.

Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

“…260 Recently, it was also found that Cerebrolysin normalized elevated levels of the proinflammatory c-reactive protein (CRP) in subjects with MCI, independently of its clinical effects. 227 These results are consistent with the previous observation of a significant increase in CRP levels over time and its lack of associations with cognition in MCI patients. 261 In AD patients of the dose-finding study, 217 Cerebrolysin enhanced serum concentrations of dissociable IGF-1 at doses of 10 and 60 ml, 162 and the levels of free IGF-1 with the 60 ml dosage.…”

“…In participants of another AD clinical trial, 218 the combination therapy with Cerebrolysin and donepezil reduced serum TNF‐α levels significantly with respect to donepezil; and TNF‐α decreases correlated with improvements in ADL functioning and cognition at study endpoint (Week 28) 260 . Recently, it was also found that Cerebrolysin normalized elevated levels of the proinflammatory c‐reactive protein (CRP) in subjects with MCI, independently of its clinical effects 227 . These results are consistent with the previous observation of a significant increase in CRP levels over time and its lack of associations with cognition in MCI patients 261 …”

“…225 In addition, changes induced by Cerebrolysin in peripheral inflammatory and neurotrophic factors were investigated in AD patients 163,169 and in subjects with MCI. 226,227…”

“…Long‐term effects of Cerebrolysin on cognitive performance and the rate of AD conversion in MCI subjects were assessed in one trial 225 . In addition, changes induced by Cerebrolysin in peripheral inflammatory and neurotrophic factors were investigated in AD patients 163,169 and in subjects with MCI 226,227 …”

Cerebrolysin improves peripheral inflammatory pain: Sex differences in two models of acute and chronic mechanical hypersensitivity

“…Cerebrolysin can penetrate the blood brain barrier (Akai et al, ; Bornstein et al, ; Muresanu et al, ; Stan, et al, ), improve functional cognitive outcomes in patients with dementia and traumatic brain injury, and improve neuro‐rehabilitation in patients with stroke (Gharagozli et al, ; Mahmoudi et al, ; Onose et al, ). More recently, there is evidence to suggest that cerebrolysin may also produce an anti‐inflammatory and analgesic effect (Dong et al, ; Mahmoudi et al, ; Malashenkova et al, ; Morales‐Medina, et al, ; Sharma et al, ). With the increasing evidence of the benefit of cerebrolysin in inflammation, we aim to build upon the findings of our previous study (Morales‐Medina et al, ) by investigating the response to acute administration of cerebrolysin in another model of peripheral inflammation and also assess sex differences.…”